Lineage Cell Therapeutics, Inc. BTX Income Statement

Lineage cell therapeutics, inc. (BTX)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
REVENUES:
Grant revenue
1,636	2,037	2,215	2,583	3,995	3,572	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalties from product sales and license fees
1,301	1,221	470	391	342	392	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	2,195	3,671	4,256	4,613	5,290	4,502	5,035	4,217	3,420	3,297	2,492	2,004	2,058	1,573	1,651	1,932	1,911	2,222	2,677	2,982	2,752	2,767	2,022	1,671	0	0	0
License fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	1,445	1,400	1,213	899	612	329	195	263	274	277	0	0	0
Royalties from product sales and license fees
-	-	-	-	-	-	-	-	-	-	-	-	454	544	552	732	763	719	706	497	456	398	397	329	357	367	425	478	501	541	595	637	688	756	784	823	0	0	0
Subscription and advertisement revenues
-	-	-	-	-	691	1,146	1,403	1,370	1,395	1,212	905	893	972	1,038	1,312	1,381	1,357	1,304	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of research products and services
-	257	316	445	0	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenues
3,101	3,515	3,032	3,447	5,215	4,988	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of research products and services
-	-	-	-	-	-	-	-	-	-	-	-	698	736	449	445	411	458	404	374	367	376	361	341	307	276	248	248	250	251	471	565	625	646	500	328	0	0	0
Total revenues
-	-	-	-	-	-	-	-	-	-	-	-	4,240	5,923	6,295	7,102	7,845	7,036	7,458	6,343	5,441	5,244	5,253	4,776	4,886	4,434	3,770	4,060	3,877	3,915	0	0	0	-	-	-	0	0	0
Total revenues
-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-
Cost of sales
438	412	341	262	261	302	304	321	220	168	94	100	190	358	529	903	1,068	1,107	1,178	977	969	837	837	813	742	793	730	693	596	434	292	147	0	-	0	0	-	-	-
Gross profit
2,663	3,103	2,691	3,185	4,954	4,686	4,925	5,614	3,549	3,290	3,450	3,255	4,050	5,565	5,766	6,199	6,777	5,929	6,280	5,366	4,472	4,407	4,416	3,963	4,143	3,641	3,040	3,366	3,280	3,481	3,558	3,480	0	-	0	0	-	-	-
OPERATING EXPENSES:
Research and development
16,326	17,948	18,242	18,858	19,981	20,955	21,872	23,552	23,465	24,024	26,339	26,199	28,866	36,106	41,883	46,894	47,015	42,604	41,025	38,428	38,450	37,533	35,564	33,169	29,618	26,609	22,144	20,248	19,333	18,116	17,268	16,211	14,929	13,699	7,962	3,045	0	0	0
Acquired in-process research and development
-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
19,890	24,031	26,560	28,373	27,342	24,726	23,504	21,669	20,865	19,922	19,455	19,442	21,655	28,426	33,306	36,277	35,827	29,134	23,700	20,417	19,067	17,556	17,018	17,024	15,810	15,559	14,653	12,620	11,412	10,365	10,166	9,819	9,808	9,341	4,727	1,273	0	0	0
Total operating expenses
36,216	41,979	70,544	72,973	72,881	46,481	20,638	20,483	42,762	43,946	22,604	22,451	27,331	64,532	75,189	83,171	82,842	71,738	64,726	58,846	57,518	55,089	70,041	67,652	62,887	59,627	36,797	32,868	30,745	28,481	27,435	26,030	24,738	23,041	12,689	10,309	0	0	0
Gain on sale of assets
-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from operations
-33,553	-38,876	-42,111	-44,046	-42,369	-41,795	-41,251	-40,407	-39,827	-38,902	-40,590	-40,632	-46,471	-58,967	-69,423	-76,972	-76,065	-65,809	-58,446	-53,480	-53,046	-50,682	-65,625	-63,689	-58,743	-55,986	-33,757	-29,502	-27,465	-25,000	-23,388	-21,674	-20,576	-18,686	-15,696	-13,780	0	0	0
OTHER INCOME/(EXPENSES):
Interest income, net
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income (expense), net
-	-	1,711	1,486	-	711	315	131	-334	-692	-1,101	-1,258	-921	-747	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of marketable equity securities
0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of AgeX shares and deconsolidation of AgeX
-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of equity method investment in Ascendance
-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income/(expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-27	-19	-9	0	4	9	12	19	25	23	24	29	21	18	0	0	0
BioTimes share of losses and impairment in equity method investment in Ascendance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-270	-35	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of shares and deconsolidation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on equity method investment in Asterias at fair value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain on equity method investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (loss) gain on marketable equity securities
-6,167	-2,898	-2,611	1,870	2,874	1,158	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized gain on warrant liability
609	611	371	752	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on extinguishment of related party convertible debt
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other (expense) income, net
376	2,532	1,593	1,004	-717	-1,699	-774	-910	546	1,449	606	576	196	-403	620	220	208	-160	-707	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-
(Loss)/gain on sale or write off of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-5	0	-	0	0	-	-	-	0	-	0	-
Modification cost of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Gain/(loss) on sale of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Other income, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-263	-184	-18	-317	-46	-66	-176	219	-159	-196	0	0	0
Total other (expense) income, net
-29,021	19,642	-17,113	68,872	93,849	-5,335	-37,393	-86,023	-98,061	15,613	86,273	96,822	139,990	77,588	77,989	38,584	3,185	3,159	-1,183	-724	-798	-473	47	119	-114	-204	-256	-179	-15	-305	0	0	0	-	-	-	0	0	0
(LOSS)/INCOME BEFORE INCOME TAXES
-62,574	-19,234	-59,224	24,826	51,480	-47,130	-78,644	-126,430	-137,888	-23,289	45,683	56,190	93,519	18,621	8,566	-38,388	-72,880	-62,650	-59,629	-54,204	-53,844	-51,155	-65,578	-63,570	-58,859	-56,191	0	0	0	-	-	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	0	0	-	-	-	-	-	-	4,772	0	3,877	0	-1,120	-2,068	-3,339	-4,516	-5,596	-6,961	-7,203	-7,376	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-
NET (LOSS)/INCOME
-59,551	-11,827	-52,255	30,804	56,210	-46,784	-73,872	-126,430	-134,011	-23,289	40,911	56,190	89,642	18,621	9,686	-36,320	-69,541	-58,134	-54,032	-47,242	-46,640	-43,779	-57,122	-57,427	-54,229	-52,910	-34,014	-29,681	-27,480	-25,305	-23,414	-21,727	-20,733	-18,443	-17,982	-16,100	0	0	0
Net loss attributable to noncontrolling interest
-133	-118	-76	-247	-658	-794	-900	-1,054	-1,199	-3,313	-5,983	-7,582	-10,330	-14,951	-20,289	-21,470	-20,451	-11,143	-8,436	-7,004	-6,573	-7,367	-8,365	-7,935	-6,707	-9,026	-3,704	-3,417	-3,308	-3,880	-2,888	-2,421	-2,606	-1,928	-1,673	-1,268	0	0	0
NET (LOSS)/INCOME ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.
-59,418	-11,709	-52,179	31,051	56,868	-45,990	-72,972	-125,376	-132,812	-19,976	46,894	63,772	99,972	33,572	25,129	-19,696	-53,936	-46,991	-41,752	-37,646	0	-	0	0	-	-43,883	-30,309	-26,264	-24,171	-21,425	-20,526	-19,306	-18,126	-16,515	-16,048	-14,570	0	0	0
NET (LOSS)/INCOME PER COMMON SHARE:
Dividends on preferred shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-36,499	-34,958	-34,205	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on available-for-sale assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-
Foreign currency translation (loss)/gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	622	-290	0	-	0	0	-	-	-
Foreign currency translation gain/(loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
TOTAL COMPREHENSIVE NET LOSS
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-20,719	-18,786	-18,352	-17,535	-16,947	-16,171	0	0	0
BASIC AND DILUTED
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.13	-	-0.12	-0.16	-0.14	-0.36	-0.16	-0.14	-0.15	-0.13	-0.10	-0.11	-0.10	-0.11	-0.08	-0.09	-0.07	-0.11	-0.06
BASIC
-0.06	-	-0.11	-0.20	0.30	-	0.53	-0.03	-0.50	-	0.12	-0.11	0.46	-0.02	0.30	0.26	-0.19	-	-0.18	-0.12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
DILUTED
-0.06	-	-0.11	-0.20	0.30	-	0.53	-0.03	-0.50	-	0.12	-0.11	0.46	-0.03	0.30	0.26	-0.19	-	-0.18	-0.12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC
149,807	-	149,659	149,582	132,865	-	126,878	126,873	126,869	-	115,288	110,874	106	388,977	102	93	90	-	79	78	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
DILUTED
149,807	-	149,659	149,582	132,869	-	126,973	126,873	126,869	-	115,298	110,874	107	397,922	103	95	90	-	79	78	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
BASIC AND DILUTED
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78,262	-	67,921	61,498	58,257	56,315	55,621	53,791	51,175	47,979	49,291	50,548	49,035	-	48,896	48,835	-	-	-
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48,306	42,653	37,562
OncoCyte Corporation [Member]
(Loss) gain on equity method investment
-	-	-	0	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on equity method investment
-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (loss) gain on equity method investment
-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Asterias Biotherapeutics [Member]
(Loss) gain on equity method investment
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on equity method investment
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (loss) gain on equity method investment
-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-